YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT

Other Chinese Firms Build Presence In Field

10 Feb 2025

• By Xu Hu

YolTech’s early clinical stage in vivo gene editing therapy YOLT-204 may provide off-the-shelf treatment in transfusion dependent β-thalassemia without conditioning chemotherapy and HSCT.

Gene editing tool — YolTech Therapeutics' first-in-class in vivo gene editing therapy, YOLT-204, in transfusion dependent β-thalassemia recently entered clinical trial. (Shutterstock)

YolTech Therapeutics, a Shanghai-based start-up focusing on in vivo gene editing, recently announced the initiation of an early Phase I trial with YOLT-204, a first-in-class therapy, in transfusion dependent β-thalassemia (TDT).

The dose-escalation study will provide a preliminary assessment of the safety, tolerability and efficacy of a single dose in three...